{
  "id": 913752,
  "title": "Histone lysine demethylase inhibition is a disease-modifying therapy for hypertrophic cardiomyopathy",
  "url": "https://urgent.news/2026/08/13/histone-lysine-demethylase-inhibition-is-a-disease-modifying-therapy",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-13T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.07.743611v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Rationale: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder characterized by cardiac hypertrophy, fibrosis, arrhythmias, and sudden cardiac death (SCD). Although current therapies primarily target sarcomere dysfunction, the contribution of epigenetic dysregulation to HCM pathogenesis and its therapeutic potential remain poorly understood. Objective: To determine whether…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}